Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Synaffix’s site-specific–conjugation and payload-enhancement technologies are improving the safety and efficacy of antibody-drug conjugates (ADCs) without the need for antibody engineering.
This Canadian biotechnology company is developing combination-treatment strategies based on monoclonal antibodies to improve clinical outcomes for cancer patients.
InDanio Bioscience Inc.’s unique Ligand Trap system provides in vivo, high-content drug discovery for compounds targeting nuclear receptors and epigenetic regulators while allowing evaluation of toxicity, bioavailability and tissue selectivity.
With two established technologies, SLPs and AMPLIVANT, ISA Pharmaceuticals is developing fully synthetic immunotherapeutic vaccines to target cancer and persistent viral infections.
By targeting noncoding mitochondrial RNA with antisense oligonucleotide drugs, Andes Biotechnologies is developing potential cancer therapies capable of inducing inhibition of cell proliferation and apoptosis.
How can you prepare for the day when an unexpected event morphs into a crisis, with all the potential negative repercussions for your company's reputation and financial standing?
